LEADING NEUROLOGY JOURNAL RELEASES PHASE III SATIVEX DATA

A leading neurology journal, The European Journal of Neurology, Feb. 28 reported a study showing that Sativex significantly reduces intractable spasticity (spasms and stiffness) in people with multiple sclerosis (MS).

The publication of these data follows the previous announcement of preliminary results of this 189 patient study, which forms part of the regulatory filing for Sativex for MS spasticity submitted in September 2006 in select European countries.

In the randomized, double-blind trial, Sativex demonstrated significant superiority to placebo in reducing spasticity in people with MS. Further, despite having achieved the maximum benefit on existing anti-spasticity medication, four out of every 10 patients achieved more than a 30 percent further improvement in their spasticity following treatment with Sativex.

The six-week study was conducted on MS patients experiencing significant levels of spasticity who failed to gain adequate relief from currently available anti-spasticity medications. Patients enrolled in the study continued to take their existing treatments throughout the tria1.